Revenue vs Net income
Reported dollars from 10-Q / 10-K filings. Q4 bars are derived (annual less nine months) where the 10-K does not tag Q4 separately.
Margin trend
Gross, operating and net margin. Margins are derived from reported dollars.
Revenue YoY growth
Year-over-year change vs the same quarter (or fiscal year) a year earlier. Shown where the prior-year period is in the 8-quarter snapshot (latest four quarters).
Income statement
From 10-Q / 10-K XBRL. Values in reported dollars; EPS in $/share; share counts in shares.
| Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5B | $7.6B | $6.7B | $7.1B | $7.8B | $7.9B | $7.0B | $7.8B |
| YoY | — | — | — | — | +3.0% | +4.7% | +4.4% | +10.2% |
| Cost of goods sold | $1.6B | $1.6B | $1.5B | $1.5B | $1.6B | $1.6B | $1.4B | $1.6B |
| YoY | — | — | — | — | -0.3% | +2.7% | -6.2% | +5.2% |
| Gross profit | — | — | — | — | — | — | — | — |
| YoY | — | — | — | — | — | — | — | — |
| Research & development | — | — | — | — | — | — | — | — |
| YoY | — | — | — | — | — | — | — | — |
| Selling, general & administrative | $1.4B | $1.9B | $1.3B | $1.4B | $1.4B | $1.8B | $1.5B | $1.9B |
| YoY | — | — | — | — | -5.3% | -5.9% | +15.3% | +40.7% |
| Operating income | $888.0M | $2.5B | $2.2B | $2.5B | $3.3B | $2.0B | $2.6B | $-10.4B |
| YoY | — | — | — | — | +274.7% | -19.1% | +15.6% | -520.1% |
| Pretax income | $956.0M | $2.2B | $1.6B | $2.4B | $3.6B | $2.1B | $2.6B | $-10.3B |
| YoY | — | — | — | — | +280.9% | -4.1% | +56.5% | -522.1% |
| Income tax | $-297.0M | $385.0M | $334.0M | $468.0M | $589.0M | $-105.0M | $559.0M | $242.0M |
| YoY | — | — | — | — | +298.3% | -127.3% | +67.4% | -48.3% |
| Net income | $1.3B | $1.8B | $1.3B | $2.0B | $3.1B | $2.2B | $2.0B | $-10.5B |
| YoY | — | — | — | — | +143.6% | +22.4% | +53.7% | -635.5% |
| EPS — basic | $1.00 | — | $1.06 | $1.57 | $2.46 | — | $1.63 | $-8.45 |
| YoY | — | — | — | — | +146.0% | — | +53.8% | -638.2% |
| EPS — diluted | $1.00 | — | $1.04 | $1.56 | $2.43 | — | $1.61 | $-8.45 |
| YoY | — | — | — | — | +143.0% | — | +54.8% | -641.7% |
| Weighted shares — basic | 1.25B | — | 1.25B | 1.25B | 1.24B | — | 1.24B | 1.24B |
| Weighted shares — diluted | 1.25B | — | 1.26B | 1.25B | 1.25B | — | 1.25B | 1.24B |
Balance sheet
Point-in-time values at each quarter (or fiscal year) end.
| Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | — | — | — | — |
| YoY | — | — | — | — | — | — | — | — |
| Marketable securities (current) | $0 | $0 | — | $69.0M | $19.0M | $68.0M | $15.0M | $0 |
| YoY | — | — | — | — | — | — | — | -100.0% |
| Accounts receivable | $4.6B | $4.4B | $4.4B | $4.8B | $5.1B | $4.9B | $4.7B | $5.1B |
| YoY | — | — | — | — | +11.1% | +11.2% | +8.0% | +5.7% |
| Inventory | $1.9B | $1.7B | $1.8B | $1.8B | $1.8B | $1.8B | $1.9B | $2.0B |
| YoY | — | — | — | — | -4.5% | +3.7% | +8.8% | +7.0% |
| Total current assets | $14.8B | $19.2B | $16.9B | $14.7B | $17.9B | $18.3B | $18.6B | $13.9B |
| YoY | — | — | — | — | +20.9% | -4.3% | +10.3% | -5.3% |
| Total assets | $54.5B | $59.0B | $56.4B | $55.7B | $58.5B | $59.0B | $56.3B | $49.4B |
| YoY | — | — | — | — | +7.4% | +0.0% | -0.3% | -11.4% |
| Total current liabilities | $11.7B | $12.0B | $12.3B | $11.2B | $12.3B | $11.8B | $9.5B | $11.0B |
| YoY | — | — | — | — | +4.9% | -1.6% | -23.2% | -1.5% |
| Total liabilities | — | — | — | — | — | — | — | — |
| YoY | — | — | — | — | — | — | — | — |
| Total equity | $18.5B | $19.3B | $19.2B | $19.7B | $21.5B | $22.7B | $23.5B | $11.8B |
| YoY | — | — | — | — | +16.6% | +17.4% | +22.7% | -39.9% |
| Shares outstanding | 1.25B | 1.25B | 1.25B | 1.24B | 1.24B | 1.24B | 1.24B | 1.24B |
| YoY | — | — | — | — | -0.3% | -0.4% | -0.2% | -0.1% |
Cash flow
Quarterly values derived from year-to-date filings (Q4 from the 10-K). Free cash flow = operating cash flow − capital expenditures.
| Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.3B | $3.0B | $1.8B | $827.0M | $4.1B | $3.3B | $2.5B | $3.6B |
| YoY | — | — | — | — | -4.7% | +11.8% | +44.8% | +332.0% |
| Capital expenditures | $141.0M | $147.0M | $104.0M | $107.0M | $147.0M | $205.0M | $117.0M | $140.0M |
| YoY | — | — | — | — | +4.3% | +39.5% | +12.5% | +30.8% |
| Free cash flow | $4.2B | $2.8B | $1.7B | $720.0M | $4.0B | $3.1B | $2.4B | $3.4B |
| YoY | — | — | — | — | -5.0% | +10.4% | +46.8% | +376.8% |
| Dividends paid | $983.0M | $973.0M | $1.0B | $994.0M | $1.0B | $994.0M | $1.0B | $1.0B |
| YoY | — | — | — | — | +2.2% | +2.2% | +3.0% | +3.5% |
| Share repurchases | $300.0M | $350.0M | $730.0M | $527.0M | $435.0M | $230.0M | $419.0M | $355.0M |
| YoY | — | — | — | — | +45.0% | -34.3% | -42.6% | -32.6% |
Margins & ratios
Derived from the reported dollars above — no separate source.
| Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 11.8% | 32.4% | 33.6% | 34.9% | 42.8% | 25.0% | 37.2% | -133.2% |
| Net margin | 16.6% | 23.6% | 19.7% | 27.7% | 39.3% | 27.5% | 29.0% | -134.5% |
| Free cash flow margin | 55.2% | 37.4% | 24.8% | 10.2% | 51.0% | 39.4% | 34.9% | 44.0% |
| Effective tax rate | -31.1% | 17.8% | 20.3% | 19.3% | 16.2% | -5.1% | 21.7% | -2.4% |
| Current ratio | 1.26x | 1.60x | 1.37x | 1.32x | 1.45x | 1.55x | 1.97x | 1.27x |
| Total liabilities / equity | — | — | — | — | — | — | — | — |
Peer comparison — latest full year
Same sector (Health Care), sorted by revenue. All figures from the same EDGAR XBRL snapshot.
| Ticker | Revenue | Revenue YoY | Gross margin | Operating margin | Net margin | FCF margin |
|---|---|---|---|---|---|---|
| GILD FY25 · this stock | $29.4B | +2.4% | — | 34.0% | 28.9% | 32.1% |
| UNH FY25 | $447.6B | +11.8% | — | 4.2% | 2.7% | 3.6% |
| CVS FY25 | $402.1B | +7.8% | — | 1.2% | 0.4% | 1.9% |
| CI FY25 | $274.9B | +11.2% | — | 3.3% | — | — |
| ELV FY25 | $199.1B | +12.5% | — | 3.6% | 2.8% | 1.6% |
| JNJ FY25 | $94.2B | +6.0% | 67.9% | — | 28.5% | 20.9% |
| LLY FY25 | $65.2B | +44.7% | — | — | 31.7% | — |
| MRK FY25 | $65.0B | +1.3% | — | — | 28.1% | 19.0% |
| ABBV FY25 | $61.2B | +8.6% | — | 24.6% | 6.9% | 29.1% |
| BMY FY25 | $48.2B | -0.2% | — | — | 14.6% | 26.7% |
| TMO FY25 | $44.6B | +3.9% | — | 17.4% | 15.0% | 14.1% |
Source: SEC EDGAR XBRL company facts (10-Q / 10-K), snapshot generated 2026-11-03 for 218 tickers. Q4 values are derived as the 10-K annual less the first nine months, since Q4 is not separately tagged in company facts; cash-flow quarterly values are derived from year-to-date filings the same way. Free cash flow = operating cash flow − capital expenditures. Blank cells mean the filing does not report that line item under a standard US-GAAP tag — nothing is estimated or filled in. Descriptive research, not investment advice. How EarnIQ builds fundamentals.